We all know about the fight against breast-cancer. But did you know that breast can also fight back?
Each year, breast cancer is the second most common cause of death in women. The American Cancer Society predicts that breast cancer will kill 40,910 Americans in 2009, despite the fact that early detection and better treatment have reduced death rates.
Breast cancer is difficult to treat. Breast cancer is usually treated by doctors using surgery to remove the tumor followed by chemotherapy and radiation. Some cancers are difficult to treat, while others return. Some tumors are resistant to chemotherapy drugs. The cancer may have developed resistance to chemotherapy drugs.
When cancer cells develop resistance to drugs, they can pump drugs out of their bodies. Some chemotherapy drugs target specific proteins in the cancer cells. Cancer cells then produce more of the protein. Because chemotherapy drugs can damage healthy tissue, doctors have to limit the amount they can give. The cancer cells produce more protein than the chemotherapy drugs can target. This allows them to overwhelm the body, even with chemotherapy.
Companies are developing innovative drugs that treat resistant cancers. This gives patients hope. Cellceutix Corporation is a drug developer that specializes in anti-inflammatory and cancer drugs. Their unique Kevetrin technology targets the growth signals of tumor cells rather than being toxic to all cells. This is an alternative to traditional chemotherapy.
The experiments involved mice being implanted with human cancer cells that were drug-resistant. Kevetrin decreased tumor volume by 68 per cent and delayed tumor growth more than 62% compared with controls.
“Kevetrin continues to demonstrate consistent success in fighting drug resistant cancers, the leading cause of chemotherapy failure,”Cellceutix CEO Mr. George Evans “We are optimistic that Kevetrin will continue to progress on the developmental pathway as a treatment for these very difficult cancers, providing hope to its patients.”
You can find more information about the Kevetrin experiments results at www.kevetrin.org www.cellceutix.com.
